Vulnerability and Risk of Neuropathic Pain in Cancer
Recruiting now · Not applicable
Conditions studied: Neuropathic Pain, Cancer, Predictive
In brief
Successive and repeated therapeutic interventions during cancer management - surgery, chemotherapy, radiotherapy - can all, to varying degrees, generate acute pain, central pain sensitization and chronic pain. Almost 58% of patients suffer from chronic pain, often of the neuropathic type, with altered quality of life and disease burden amplified by difficulty in achieving effective relief. Indeed, neuropathic pain in cancer remains difficult to treat, often arrives insidiously, may persist well beyond cancer remission, and frequently has a fate that is difficult to predict. Current treatments for neuropathic pain are based on the recommendations of learned societies, but therapeutic failures are frequent, and iatrogenic pathology is high. Many factors have been identified as being associated with the development of chronic pain in cancer patients. The intensity of preoperative pain, opioid consumption, age, sleep disorders, cognitive-emotional state, psychological vulnerability and social precariousness are all factors that influence and perpetuate chronic pain linked to cancer and its management. Several studies have shown that 6 months or 1 year after cancer diagnosis, there are various pain trajectories, enabling us to identify several pain patient phenotypes. The patient's overall state of vulnerability at the time of cancer diagnosis has an impact on the trajectory of pain chronicisation, and it is often difficult for clinicians to apprehend this risk. In practice, we lack a validated, easy-to-use tool that would enable us to predict the risk of pain chronicisation for each patient, even before the start of the treatment process.
Key facts
- Study ID
- NCT06511674
- Run by
- University Hospital, Clermont-Ferrand
- People needed
- 625
- Starts
- 2024-10-28
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2025-12-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Institut Gustave Roussy — Villejuif, France (enrolling)
- Centre de Lutte contre le Cancer - Institut de Cancérologie de l'Ouest — Angers, France (enrolling)
- Centre Hospitalier Henri Mondor d'Aurillac — Aurillac, France (enrolling)
- Centre de Lutte contre le Cancer - Institut Bergonié — Bordeaux, France (enrolling)
- Centre de Lutte contre le Cancer - Centre François Baclesse — Caen, France (enrolling)
- Centre Hospitalier Universitaire Caen Normandie — Caen, France (enrolling)
- Centre de Lutte contre le Cancer - Jean Perrin — Clermont-Ferrand, France (enrolling)
- CHU de Clermont-Ferrand — Clermont-Ferrand, France (enrolling)
- Hôpitaux civils de Colmar — Colmar, France (enrolling)
- Centre Régional de Lutte contre le Cancer - Georges Francois Leclerc — Dijon, France (enrolling)
- Hôpital privé le Bois — Lille, France (enrolling)
- Centre Hospitalier d'Ajaccio — Ajaccio, France (enrolling)
- Centre Hospitalier de Moulins-Yzeure — Moulins, France (enrolling)
- Hôpital Saint-Louis APHP — Paris, France (enrolling)
- Hôpital Beaujon AP-HP — Paris, France (enrolling)
- Institut Godinot — Reims, France (enrolling)
- Centre Hospitalier Yves Le Foll — Saint-Brieuc, France (enrolling)
- CH Valenciennes — Valenciennes, France (enrolling)
- Centre Hospitalier de Montluçon — Montluçon, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.